Bill & Melinda Gates Foundation
TB Vaccine
Accelerator Program
Deadline for Letters of Inquiry: November 26, 2012
BMGF is requesting applications for projects that will help meet
one, or both, of the following interrelated goals:
- To develop novel approaches to vaccination against Mycobacterium tuberculosis (Mtb), with a particular focus on approaches that aim to induce protection against infection with Mtb.
- To develop models of natural Mtb transmission and methods for defining the relevant molecular and biological characteristics of naturally transmitted mycobacteria and of their interactions with vertebrate hosts
The prevention of tuberculosis (TB) through the
development and deployment of an effective vaccine is a priority of the Bill
& Melinda Gates Foundation. To
strengthen the pipeline of vaccine candidates and enable a more rational and
accelerated vaccine development process, the foundation, in collaboration with
its Product Development Partner Aeras, recently launched the TB Vaccine
Accelerator Program. With the assistance
and support of the TB research and development community, a set of obstacles to
TB vaccine development—and integrated goals that, collectively, could help to
directly understand, overcome or work around these obstacles—have been
selected. Through a research program
focused on achieving this defined set of interdependent goals, the TB Vaccine
Accelerator aims to address significant challenges in this field. This Request for Applications (RFA) focuses
on two of these goals.
The complete RFA, along with instructions for submitting
a Letter of Inquiry, can be found at:
Interested applicants are asked to read the RFA document.
Deadline for Letters of Inquiry: November 26, 2012
Please also be sure to check back at www.grandchallenges.org for ongoing
funding opportunities.
